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Abstract Neuroblastoma X glioma NG108-15 hybrid cells have 
been examined for the expression of opioid receptor-like receptor 
(ORL,). [3H|Nociceptin/orphanin FQ (OFQ) bound to the cell 
membrane specifically (KA = 3.6 ± 0.6 nM) and inhibited for-
skolin-stimulated cAMP accumulation (ECS 0 = 0.72 ± 0.3 nM). 
The responsiveness of NG108-15 cells to nociceptin/OFQ was 
blocked by pertussis toxin but not by naltrindole. The inhibitory 
activity of nociceptin/OFQ was significantly reduced after a 
prechallenge with the same peptide but was not influenced by 
D P D P E pretreatment, indicating acute and homologous desen-
sitization of ORLi receptors. Naltrindole caused the overshoot of 
cAMP in DPDPE-pretreated cells but not in nociceptin/OFQ-
pretreated cells. The results indicate that ORL t is functionally 
expressed and does not cross-interact with specific ligands of the 
8 opioid receptor in NG108-15 cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Opioids are clinically effective analgesics. Through interac-
tion with endogenous opioid peptides and exogenous opioid 
alkaloids, opioid receptors mediate numerous physiological 
and pharmacological effects. Three subtypes of the opioid 
receptors (u, 8, and K) have been identified through their 
different affinities for various opioid ligands [1]. These opioid 
receptors are all coupled to the inhibitory G protein (Gi) and 
negatively regulate adenylyl cyclase [1]. Recently, another Gi 
protein coupled receptor, opioid receptor-like receptor 
(ORLi) , has been cloned from brain [2-8]. Its endogenous 
specific agonist nociceptin/orphanin F Q (OFQ) has also 
been identified [9,10]. Nociceptin/OFQ specifically binds to 
O R L i exogenously expressed in C H O cells and inhibits for-
skolin-stimulated c A M P accumulation. But in contrast to the 
analgesic effects of most opioids, nociceptin/OFQ induces hy-
peralgesia in animals [9,10]. The cellular and molecular mech-
anisms underlying nociceptin's anti-opioid (hyperalgesic) ef-
fects are yet to be understood. A neuronal cellular model 
system is needed to study nociceptin/OFQ-ORLi mediated 
signal transduction and possible interactions of O R L i with 
other opioid receptors. In the present study, we report that 
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neuroblastoma X glioma NG108-15 hybrid cells, which express 
the 8 opioid receptor, also endogenously express functional 
O R L i . Our study demonstrated that ORLi can be acutely 
and homologously desensitized by nociceptin/OFQ and that 
nociceptin/OFQ does not cross-interact with the 8 opioid re-
ceptor in NG108-15 cells. 
2. Materials and methods 
2.1. Cell cultures 
Neuroblastoma X glioma NG108-15 hybrid cells were cultured in 
DMEM (Gibco) supplemented with 10% heat-inactivated fetal calf 
serum (Evergreen, Hangzhou, China), 100 units/ml penicillin, 100 
ug/ml streptomycin and 2 mM glutamine as described previously [11]. 
2.2. Membrane preparation and nociceptinlOFQ-ORLi binding assay 
Cells were harvested and homogenized in 50 mM Tris-HCl, pH 7.4. 
The homogenates were centrifuged at 38 000 Xg for 15 min at 4°C and 
the pellets were resuspended in 50 mM Tris-HCl, pH 7.4, and 0.1% 
bovine serum albumin (BSA, Sigma). The membrane preparations 
were homogenized again just before use. 
Membrane protein (0.5 mg) was incubated with different concen-
trations of [3H]nociceptin/OFQ (33 Ci/mmol, Phoenix Pharmaceuti-
cals, Inc., California) in 0.4 ml of 50 mM Tris-HCl, pH 7.4, and 1% 
BSA at 30°C for 1 h. The reaction was terminated by filtering through 
GF-B filters presoaked with 0.1% polyethyleneimine. After washing, 
the nociceptin/OFQ bound to the membrane was determined by meas-
uring radioactivity remaining on the filter in a scintillation counter. 
Non-specific binding was determined in the presence of 50 uM unla-
belled nociceptin/OFQ (Tocris Cookson Ltd, UK) and was subtracted 
from the total binding. 
2.3. Cyclic AMP assay 
Cells were challenged with nociceptin/OFQ or DPDPE in the pres-
ence of 1 uM forskolin and 500 U.M l-methyl-3-isobutylxanthine 
(IBMX, Sigma) at 37°C for 10 min. The reactions were terminated 
with 1 N perchloric acid and neutralized with 2 N K2CO3. The cAMP 
level of each sample was determined using radioimmunoassay as de-
scribed previously [11]. Data were averages of triplicate samples and 
are presented as a percentage of control (in the presence of forskolin 
alone). 
2.4. Receptor desensitization and cAMP overshooting 
NG108-15 cells were prechallenged with 0, 0.1, 1, or 10 uM of 
nociceptin/OFQ or 10 uM [D-Pen2,D-Pen5]-enkephalin (DPDPE, Sig-
ma) at 37°C for 10 min. The cells were then washed twice with phos-
phate buffered saline and challenged again with 1 u,M of nociceptin/ 
OFQ or 1 uM DPDPE. In the experiment of overshoot of cellular 
cAMP levels, cells were preincubated with nothing, 1 uM of nocicep-
tin/OFQ or DPDPE at 37°C for 2 h and washed four times with 
phosphate buffered saline. The cAMP accumulation was determined 
10 min after addition of 10 uM of naltrindole (Sigma) or naloxone 
(Sigma). The cellular cAMP levels were measured as described above. 
3. Results 
Membrane fractions were prepared from NG108-15 cells, 
and the presence of ORLi receptors was examined using 
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[3H]nociceptin/OFQ, a specific agonist of ORLi [9,10]. As 
shown in Fig. 1A, binding of nociceptin/OFQ to NG108-15 
was specific and saturable. Analysis of saturation binding data 
indicates a dissociation constant of 3.6±0.6 nM and 5 m a x of 
155 + 14 fmol/mg protein, comparable to the value obtained in 
rat brain homogenates [12] 
The function of the ORLi receptors expressed in NG108-15 
cells was also assessed. As shown in Fig. IB, nociceptin/OFQ 
strongly inhibited forskolin-stimulated cAMP accumulation in 
a dose-dependent manner, indicating functional expression of 
ORLi receptor in NG108-15 cells. The nociceptin/OFQ in-
duced attenuation of cAMP accumulation occurred at nano-
molar concentrations of nociceptin (EC50 — 0.72 ± 0.3 nM) and 
reached maximum inhibition at micromolar concentrations of 
nociceptin/OFQ, consistent with that observed in ORLx trans-
fected CHO cells (EC50 =0.9 and 1 nM [9,10]). 
ORLi is negatively coupled to G-protein and its activation 
attenuates cellular cAMP accumulation [9,10]. As shown in 
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Fig. 1. Functional expression of ORLi. A: Saturation binding of 
3H-labeled nociceptin/OFQ to NG108-15 cells. Membrane prepara-
tions from NG108-15 cells were incubated with various concentra-
tions of [3H]nociceptin/OFQ, and the [3H]nociceptin/OFQ bound to 
membranes was determined as described in Section 2. The Scatchard 
plot obtained from the saturation curve is shown as an inset. The 
Ki of nociceptin/OFQ was calculated to be 3.6 ±0.6 nM, and the 
5max 155±14 fmol/mg protein. B: The dose-response curve for in-
hibition of forskolin stimulated accumulation of cellular cAMP by 
nociceptin/OFQ. NG108-15 cells were incubated with various con-
centrations of nociceptin/OFQ at 37°C for 10 min and the cAMP 
accumulation was determined as described in Section 2. The EC50 
of nociceptin/OFQ inhibition was 0.72 + 0.3 nM. The figure is repre-
sentative of three independent experiments. Each value is the aver-
age of triplicate samples. 
Nociceptin/OFQ DPDPE 
Fig. 2. Effects of PTX and naltrindole on the activity of nociceptin/ 
OFQ. A: Cells were pretreated with or without 200 ng/ml PTX for 
24 h, and then were challenged with 1 uM of nociceptin/OFQ or 
DPDPE at 37°C for 10 min. B: Cells were challenged, in the ab-
sence or presence of 10 uM naltrindole, with 1 |iM of nociceptin/ 
OFQ or DPDPE at 37°C for 10 min. The cAMP accumulation was 
determined and is presented as a percentage of control. Plotted is 
the percentage of cAMP accumulation from at least three experi-
ments (means ± S.E.). Student's Mest was used for statistical analy-
sis of data. *P<0.05; **P<0.01; *"P< 0.005. 
Fig. 2A, pretreatment of the cells with pertussis toxin 
(PTX), a blocker of Gi/Go, completely abolished nociceptin/ 
OFQ induced inhibition of cAMP accumulation. This sug-
gests that PTX-sensitive G protein(s) is required for the in-
hibitory effect of nociceptin/OFQ in NG108-15 cells. The data 
also confirm that ORLi, a putative Gi protein coupled recep-
tor, is functionally expressed in the neuronal NG108-15 cells. 
NG108-15 is a clonai, neuronal cell line which has long 
been used as a cellular model for opioid receptor studies. It 
has been demonstrated that the NG108-15 cells contain a 
homogeneous population of opiate receptors, the 6 subtype 
[13,14]. Like ORLi and other opioid receptors, the 8 opioid 
receptor is coupled to Gi protein [1,15]. To exclude any prob-
able contribution of the 8 opioid receptor to nociceptin/OFQ's 
inhibition of cAMP accumulation, we tested the ability of 
naltrindole, a 8-specific antagonist, to block nociceptin in-
duced attenuation of cAMP accumulation. As shown in Fig. 
2B, treatment of NG108-15 cells with the 8-specific antagonist 
naltrindole did not affect the ability of nociceptin to inhibit 
forskolin stimulated cAMP accumulation. In contrast, naltrin-
dole completely blocked DPDPE induced inhibition of cAMP 
accumulation, suggesting that DPDPE does not cross-activate 
ORLi under the experimental conditions. The above data 
clearly indicate that nociceptin/OFQ does not activate the 8 
opiate receptor and the 8 opioid receptor is apparently not 
involved in nociceptin induced attenuation of cAMP accumu-
lation in NG108-15 cells. 
Opioid receptor desensitization, the reduced responsiveness 
of the opioid receptor/Gi system after opioid stimulation, has 
been implicated as one of the molecular mechanisms under-
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Fig. 3. Desensitization of ORLi and cAMP overshooting. A: Cells 
were pretreated with 0, 0.1, 1, or 10 uM nociceptin/OFQ at 37°C 
for 10 min and washed with phosphate buffered saline. The cells 
were then challenged again with 1 uM of nociceptin. B: Cells were 
pretreated with nothing, 10 U.M of nociceptin/OFQ, or 10 uM 
DPDPE at 37°C for 10 min, and then challenged again with 1 uM 
of nociceptin/OFQ (Noci/OFQ) or 1 uM DPDPE. C: Cells were 
preincubated with nothing, 1 uM of nociceptin/OFQ, or 1 uM 
DPDPE at 37°C for 2 h, and washed with phosphate buffered sal-
ine. The cAMP accumulation was determined 10 min after 10 uM 
of naltrindole or naloxone was added to the cells. Plotted is the per-
centage of cAMP accumulation from at least three experiments 
(means ± S.E.). Student's /-test was used for statistical analysis of 
data. *P<0.05; **P<0.01; ™ P < 0.005. 
lying opioid tolerance. To examine the ability of nociceptin to 
induce desensitization of ORLi and the 8 opioid receptors, 
NG108-15 cells were pretreated with the ORLx endogenous 
agonist nociceptin/OFQ or the 8 opioid receptor-specific ago-
nist DPDPE, and the ability of nociceptin or DPDPE to in-
hibit forskolin stimulated cAMP accumulation was deter-
mined. As shown in Fig. 3A, the inhibition on cAMP 
accumulation was abolished after a brief prechallenge with 
nociceptin/OFQ, indicating that ORLi receptor undergoes 
acute desensitization. However, prechallenge with nociceptin 
did not change inhibition of cAMP accumulation induced by 
DPDPE, a 8-specific agonist (Fig. 3B). Moreover, pretreat-
ment of DPDPE desensitized only the 8 opioid receptor, but 
did not attenuate cAMP accumulation stimulated with the 
ORLi-specific agonist nociceptin/OFQ (Fig. 3B). This sug-
gests that desensitization of ORLi is agonist-specific (i.e. ho-
mologous), and ORLi is not cross-desensitized by the 8-spe-
cific agonist in NG108-15 cells. 
In addition to desensitization of opioid receptors, a com-
pensatory increase in adenylyl cyclase activity could be ob-
served in cells when opioid receptor was activated for an ex-
tended period of time. The compensatory increase in cellular 
cAMP level, cAMP overshoot, could be observed either by 
removal of agonist or by addition of antagonist after chronic 
treatment with 8 opioid agonist in NG108-15 cells [13] and 
neuroblastoma NS20Y cells [16]. The cAMP overshooting was 
also observed with u, opioid receptor in human neuroblastoma 
SH-SY5Y cells [17]. We next investigated if administration of 
a non-specific opiate antagonist or a 8-specific antagonist after 
chronic treatment with nociceptin/OFQ causes cAMP over-
shoot. NG108-15 cells were prechallenged with nothing, 
1 uM of nociceptin/OFQ or 1 uM DPDPE for 2 h, and 
cAMP accumulation was determined 10 min after addition 
of naltrindole or naloxone. As shown in Fig. 3C, administra-
tion of naloxone, a non-specific antagonist of opioid recep-
tors, increased intracellular cAMP levels by approximately 
100% in both DPDPE- and nociceptin/OFQ-treated cells. 
However, when naltrindole, a 8-specific antagonist, was 
added, cAMP overshoot was observed only in the cells pre-
challenged with the 8-specific agonist DPDPE-prechallenged 
cells, not in the cells treated with the ORLi-specific agonist 
nociceptin/OFQ (Fig. 3C). This indicates that continuous ac-
tivation of ORLi results in a compensatory increase of ad-
enylyl cyclase activity, and confirms that the inhibitory activ-
ity of nociceptin/OFQ on cAMP accumulation was not 
mediated by the 8 opioid receptor in NG108-15 cells. 
4. Discussion 
The anti-opioid effect mediated by ORLi [9,10] suggests 
that ORLi, like other opioid receptors, plays an important 
role in pain modulation. The molecular and cellular mecha-
nisms of the ORLx mediated anti-analgesic effect are not yet 
understood. Although it has been demonstrated that activa-
tion of ORLi inhibits adenylyl cyclase in CHO cells exoge-
nously transfected with ORLi, the function and signal trans-
duction processes of ORLi have not been studied in a 
neuronal cellular environment. Our present study using 
NG108-15 cells revealed that this neuronal cell line endoge-
nously expresses functional ORLi. The receptor binding ex-
periments indicated that nociceptin/OFQ binds to the NG108-
15 cell membrane in a dose-dependent and saturable manner, 
with a dissociation constant of 3 nM (Fig. 1A). Nociceptin/ 
OFQ also strongly inhibited forskolin-stimulated cAMP accu-
mulation in NG108-15 cells. The EC50 of the inhibitory activ-
ity of nociceptin/OFQ was 0.7 nM (Fig. IB), consistent with 
values determined in CHO cells previously [9,10]. Further-
more, PTX strongly blocked the inhibitory effect of nocicep-
tin/OFQ (Fig. 2A), suggesting involvement of Gi coupled re-
ceptors. The above data indicate the endogenous and 
functional expression of ORLi in NG108-15 cells. The K& 
observed for nociceptin binding to ORLi (3.6 ± 0.6 nM) in 
NG108-15 cells is comparable to the value obtained in rat 
brain (5 ±1.1 nM [12]). However, the reported K& value in 
non-neuronal CHO cells exogenously transfected with ORLi 
is lower (0.1 nM [10]). This may reflect differences in mem-
brane environment of neuronal versus non-neuronal cells. 
Like (x, 8, and K opioid receptors, the newly discovered 
ORLi is also widely expressed throughout the brain and spi-
nal cord as detected by Northern blotting, in situ hybridiza-
tion and immunohistochemistry [2,3,5,18]. The expression of 
ORLi overlaps with that of other opioid receptors in many 
regions of the central nervous system. Furthermore, ORLx 
94 L. Ma et al.lFEBS Letters 403 (1997) 91-94 
mediates an anti-opioid effect as demonstrated in animal ex-
periments [9,10], suggesting that ORLi may interact directly 
or indirectly with opioid receptors. However, it has not been 
demonstrated that ORLi co-expresses endogenously with \i, 8, 
or K opioid receptors in any neuronal cells. NG108-15 cells 
have been used as a cellular model system for opioid research. 
It has been previously observed that this clonai cell line endo-
genously expresses a homogeneous population of opioid re-
ceptors, the 8 opioid receptors [13,14]. Our present study re-
vealed that this neuronal cell line endogenously and 
functionally expresses both ORLi and the 8 opioid receptors. 
Treatment of NG108-15 cells with naltrindole, a specific an-
tagonist of the 8 opioid receptor, did not significantly change 
the inhibitory effect of nociceptin/OFQ on cellular cAMP ac-
cumulation, while the same treatment abolished the inhibitory 
effect of DPDPE (Fig. 2B), indicating that the inhibitory func-
tion of nociceptin/OFQ on cAMP accumulation observed in 
NG108-15 cells is not mediated by the 8 opioid receptor. 
Chronic administration of opiates results in tolerance and 
dependence. However, the mechanisms underlying this are 
largely unknown. Desensitization, phosphorylation, and 
down-regulation of opioid receptors, and postreceptor intra-
cellular messenger pathways including up-regulation of the 
cAMP pathway have been implicated in opioid tolerance 
and dependence [19-21]. The work of Law et al. and our 
group has demonstrated that the 8 opioid receptors in 
NG108-15 cells undergo chronic and acute homologous de-
sensitization [11,13]. Our present study provides the first re-
port of acute and homologous desensitization of ORLi recep-
tors. In addition to receptor desensitization, chronic 
administration of opioid increases levels of expression of ad-
enylyl cyclase and protein kinase A in locus ceruleus neurons. 
Removal of the opiate leads to cAMP overshoot and this 
contributes to the activation of locus ceruleus neurons during 
withdrawal [18]. In the current study, we examined the effect 
of chronic treatment with nociceptin/OFQ on the activation of 
adenylyl cyclase in NG108-15 cells. The data showed that 
addition of naloxone results in overshoot of cAMP in the cells 
chronically exposed to nociceptin/OFQ (Fig. 3C). Administra-
tion of naltrindole caused the overshooting of cAMP levels in 
DPDPE-pretreated cells but not in cells pretreated with noci-
ceptin/OFQ. Taken together, the above results show that 
ORLi, upon pretreatment with nociceptin/OFQ, undergoes 
acute desensitization and up-regulates cellular cAMP. The 
results also suggest that ORLi does not cross-interact with 
or cannot be desensitized by specific ligands of the 8 opioid 
receptor. 
Nociceptin/OFQ exerts an anti-opioid effect in animal ex-
periments [9,10]. However, it is very homologous to the opioid 
receptors in structure and its distribution largely overlaps with 
opioid receptors. Like opioid receptors, ORLi is negatively 
coupled to the G protein and activation of ORLi causes at-
tenuation of cellular cAMP accumulation. The molecular and 
cellular mechanisms behind the anti-opioid effect mediated by 
ORLi are still a mystery. The NG108-15 cell line, as we have 
demonstrated, endogenously and functionally expresses 
ORLi. It will serve as an excellent cellular model to study 
ORLi mediated signal transduction in neuronal cells. The 
presence of well characterized 8 opioid receptor in NG108-
15 cells allows us to study the interactions between the ORLi 
and opioid receptor mediated signal transduction pathways in 
a natural, neuronal cellular environment. 
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